Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company -- Ignore unavailable to you. Want to Upgrade?

To: serndip who wrote (1)	7/21/2006 9:08:24 AM
From: rareearth42	Read Replies (3) \| Respond to of 90

serndip, The phase 3 trials for Talabostat are underway for non-small cell lung cancer, that's the malignancy where they saw 2 complete remissions of 42 treated. There are 2 parallel trials, one in combination with pemetrexed and the other in combination with docetaxel. Each will include several hundred patients, they're being done at multiple sites, here's the link to the clinicaltrials site with more info: clinicaltrials.gov They're in phase 2 with studies in melanoma and earlier studies in chronic lymphocytic leukemia and a couple of others. Take a look at their website to get started: pther.com These small companies with essentially just one drug that will make or break them can be very risky, but they're studying NSCLC patients who've failed platinum-based chemo (and they all eventually fail, since it's not a cure)so the bar is set pretty low. Just a few months of additional survival would have the oncologists excited, and they see some complete remissions, so I am pretty optimistic. I wouldn't bet the farm, but 10K-50K shares wouldn't be unreasonable to risk. RE42